PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29953997-6	2018	Sublethal concentrations of CDDO-me suppressed STAT3 activation by W4P-LHB ectopic expression and interleukin-6 treatment in W4P-LHB-NIH3T3 and Huh7 cells respectively.	bardoxolone methyl	28-35	interleukin 6	Homo sapiens	98-111	
34573098-8	2021	Treatment with RTA402 results in antiapoptotic, antioxidative stress, anti-inflammatory, and myelin-preserving effects on retinal ganglion cell (RGC) survival and visual function via regulation of NQO1 and HO-1, reduced IL-6 and Iba1 expression in macrophages, and promoted microglial expression of TGF-beta and Ym1 + 2 in the retina and optic nerve.	bardoxolone methyl	15-21	interleukin 6	Homo sapiens	220-224	
35265066-5	2022	We also demonstrated that addition of CDDO-Me to tri-cultures enhanced T cell-mediated reductions in CCL2, VEGF and IL-6 production in a contact-independent manner.	bardoxolone methyl	38-45	interleukin 6	Homo sapiens	116-120	
23741300-7	2013	On day 7, CDDO-Me reduced total BALF protein by 50%, alveolar macrophage infiltration by 40%, neutrophil infiltration by 90% (p<=0.01), inhibited production of the inflammatory cytokines KC and IL-6 by over 90% (p<=0.001), and excess production of the pro-fibrotic cytokine TGFbeta by 50%.	bardoxolone methyl	10-17	interleukin 6	Homo sapiens	197-201	
26918785-4	2016	We show that CDDO-Me treatment inhibits expression of IL-10 and VEGF in stimulated human M2 macrophages and TAMs but increases expression of TNF-alpha and IL-6.	bardoxolone methyl	13-20	interleukin 6	Homo sapiens	155-159	
25105464-9	2014	Peripheral blood mononuclear cells showed a trend toward increased IL-6 gene expression after CDDO-Me treatment, whereas purified monocytes showed a trend toward decreased IL-6.	bardoxolone methyl	94-101	interleukin 6	Homo sapiens	67-71	
18587580-0	2009	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.	bardoxolone methyl	0-7	interleukin 6	Homo sapiens	58-62	
18587580-3	2009	To explore potential therapeutic strategies for interrupting signaling through this pathway, we assessed the ability of CDDO-Me, a synthetic triterpenoid, to inhibit IL-6 secretion, Stat3 phosphorylation, Stat3 nuclear translocation and paclitaxel sensitivity in several cell line model systems.	bardoxolone methyl	120-127	interleukin 6	Homo sapiens	166-170	
18587580-4	2009	These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation.	bardoxolone methyl	32-39	interleukin 6	Homo sapiens	63-67	
18587580-4	2009	These studies demonstrated that CDDO-Me significantly inhibits IL-6 secretion in paclitaxel-resistant ovarian cancer cells and specifically suppresses IL-6- or oncostatin M-induced Stat3 nuclear translocation.	bardoxolone methyl	32-39	interleukin 6	Homo sapiens	151-156	
18587580-8	2009	Our data confirm that CDDO-Me interrupts the signaling of multiple kinases involved in the IL-6-Stat3 and Src signaling pathways.	bardoxolone methyl	22-29	interleukin 6	Homo sapiens	91-101	
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	interleukin 6	Homo sapiens	45-58	
18413761-3	2008	The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells.	bardoxolone methyl	30-37	interleukin 6	Homo sapiens	60-64	
18413761-5	2008	In concert with these results, CDDO-Me blocked IL-6-induced and constitutive activation of signal transducer and activator of transcription 3 (STAT3).	bardoxolone methyl	31-38	interleukin 6	Homo sapiens	47-51